AQP4 and neuromyelitis optica: Currently, the clinical diagnosis of NMOSD is mainly based on the detection of serum NMO-IgG (AQP4-IgG) antibodies and the presence of core symptoms included in the diagnostic criteria developed by the International Panel for NMO Diagnosis in 2015 (Table 1) [10,12,13].